Key Takeaways Telix Pharmaceuticals reported that the U.S. Food and Drug Administration approved its agent indicated for ...
The University of Massachusetts Lowell, Department of Chemistry, invites you to attend a Master’s Thesis defense by Madelyn Hallisey on “Novel PET Radiochemistry: Adapting Analytical and ...
A recent study provided key insights into brain degeneration in DLB, which may help clinicians better monitor this ...
The Alzheimer’s Disease Research Center (ADRC) at the University of Pittsburgh is one of the country’s hubs for researchers ...
Neurodegenerative diseases represent a significant challenge in medical science, impacting millions globally. Despite advancements in diagnostic technology, ...
TechneLite. Rounding out Lantheus’ meaningful contributors to its top line is TechneLite, a generator of technetium, a ...
Medical Device Network on MSN5d
Telix’s prostate cancer imaging agent approved in BrazilBrazilian Health Regulatory Agency (ANVISA) has granted approval for Telix Pharmaceuticals’ Illuccix, a prostate cancer ...
In a study of biomarkers in Alzheimer’s dementia, plasma p-tau217 had greater agreement with CSF and amyloid-PET biomarker ...
Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential ...
MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback